Section Arrow
RPRX.NASDAQ
- Royalty Pharma plc
Quotes are at least 15-min delayed:2025/06/04 03:54 EDT
Last
 33.29
+0.03 (+0.09%)
Day High 
33.54 
Prev. Close
33.26 
1-M High
34.315 
Volume 
3.41M 
Bid
--
Ask
--
Day Low
32.85 
Open
33.13 
1-M Low
31.97 
Market Cap 
14.01B 
Currency USD 
P/E 13.58 
%Yield 2.58 
10-SMA 32.9 
20-SMA 32.94 
50-SMA 32.43 
52-W High 34.315 
52-W Low 24.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.45/3.42
Enterprise Value
20.63B
Balance Sheet
Book Value Per Share
15.87
Cash Flow
Cash Flow Yield
0.14
Income Statement
Total Revenue
2.26B
Operating Revenue Per Share
5.52
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed:2025/06/04 03:54 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.